DSpace@İnönü

Yazar "Cabuk, D" için Araştırma Çıktıları | Pubmed İndeksli Yayınlar Koleksiyonu listeleme

Yazar "Cabuk, D" için Araştırma Çıktıları | Pubmed İndeksli Yayınlar Koleksiyonu listeleme

Sırala: Sıra: Sonuçlar:

  • Efficacy of sorafenib in advanced differentiated and medullary thyroid 
    Benekli, M; Yalcin, S; Ozkan, M; Elkiran, ET; Sevinc, A; Cabuk, D; Coskun, HS; Oksuzoglu, B; Bayar, B; Akbulat, A; Ozet, A (2015)
    Background: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib ...
  • Efficacy of sorafenib in advanced differentiated and medullary thyroid 
    Benekli, M; Yalcin, S; Ozkan, M; Elkiran, ET; Sevinc, A; Cabuk, D; Coskun, HS; Oksuzoglu, B; Bayar, B; Akbulat, A; Ozet, A (2015)
    Background: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib ...
  • Efficacy of sorafenib in advanced differentiated and medullary thyroid 
    Benekli, M; Yalcin, S; Ozkan, M; Elkiran, ET; Sevinc, A; Cabuk, D; Coskun, HS; Oksuzoglu, B; Bayar, B; Akbulat, A; Ozet, A (2015)
    Background: Antivascular endothelial growth factor tyrosine kinase inhibitors have been used recently in the treatment of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Off-label sorafenib ...
  • Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas 
    Cicin, I; Ozatli, T; Turkmen, E; Ozturk, T; Ozcelik, M; Cabuk, D; Gokdurnali, A; Balvan, O; Yildiz, Y; Seker, M; Ozdemir, N; Yapar, B; Tanriverdi, O; Gunaydin, Y; Menekse, S; Oksuzoglu, B; Aksoy, A; Erdogan, B; Hacioglu, MB; Arpaci, E; Sevinc, A (2016)
    Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are ...
  • Pertuzumab, trastuzumab and taxane-based treatment for visceral organ 
    Esin, E; Oksuzoglu, B; Bilici, A; Cicin, I; Kostek, O; Kaplan, MA; Aksoy, S; Aktas, BY; Ozdemir, O; Alacacioglu, A; Cabuk, D; Sumbul, AT; Sakin, A; Paydas, S; Yetisir, E; Er, O; Korkmaz, T; Yildirim, N; Sakalar, T; Demir, H; Artac, M; Karaagac, M; Harputluoglu, H; Bilen, E; Erdur, E; Degirmencioglu, S; Aliyev, A; Cil, T; Olgun, P; Basaran, G; Gumusay, O; Demir, A; Tanrikulu, E; Yumuk, PF; Imamoglu, I; Oyan, B; Cetin, B; Haksoyler, V; Karadurmus, N; Erturk, I; Evrensel, T; Yilmaz, H; Beypinar, I; Kocer, M; Pilanci, KN; Seker, M; Urun, Y; Eren, T; Demirci, U (2019)
    PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study ...
  • Pertuzumab, trastuzumab and taxane-based treatment for visceral organ 
    Esin, E; Oksuzoglu, B; Bilici, A; Cicin, I; Kostek, O; Kaplan, MA; Aksoy, S; Aktas, BY; Ozdemir, O; Alacacioglu, A; Cabuk, D; Sumbul, AT; Sakin, A; Paydas, S; Yetisir, E; Er, O; Korkmaz, T; Yildirim, N; Sakalar, T; Demir, H; Artac, M; Karaagac, M; Harputluoglu, H; Bilen, E; Erdur, E; Degirmencioglu, S; Aliyev, A; Cil, T; Olgun, P; Basaran, G; Gumusay, O; Demir, A; Tanrikulu, E; Yumuk, PF; Imamoglu, I; Oyan, B; Cetin, B; Haksoyler, V; Karadurmus, N; Erturk, I; Evrensel, T; Yilmaz, H; Beypinar, I; Kocer, M; Pilanci, KN; Seker, M; Urun, Y; Eren, T; Demirci, U (2019)
    PurposeIn this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients.MethodsThis study ...
  • The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab 
    Ozdemir, O; Zengel, B; Yildiz, Y; Uluc, BO; Cabuk, D; Ozden, E; Salim, DK; Paydas, S; Demir, A; Diker, O; Pilanci, KN; Sonmez, OU; Vatansever, S; Dogan, I; Gulmez, A; Cakar, B; Gursoy, P; Yildirim, ME; Ayhan, M; Karadurmus, N; Aykan, MB; Cevik, GT; Sakalar, T; Hacibekiroglu, I; Gulbagci, BB; Dincer, M; Garbioglu, DB; Kemal, Y; Nayir, E; Taskaynatan, H; Yilmaz, M; Avci, O; Sari, M; Coban, E; Atci, MM; Esen, SA; Telli, TA; Karatas, F; Inal, A; Demir, H; Kalkan, NO; Yilmaz, C; Tasli, F; Alacacioglu, A (2022)
    In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted ...
  • Real life experience of patients with locally advanced gastric and 
    Basoglu, T; Sakin, A; Erol, C; Ozden, E; Cabuk, D; Cilbir, E; Ozyukseler, DT; Ayhan, M; Sendur, MA; Dogan, M; Oksuzoglu, B; Eryilmaz, MK; Er, O; Tasci, ES; Ozyurt, N; Dulgar, O; Ozen, M; Hacibekiroglu, I; Oner, I; Bekmez, ET; Yildirim, HC; Yalcin, S; Paydas, S; Yekeduz, E; Aksoy, A; Ozcelik, M; Oyman, A; Almuradova, E; Karabulut, B; Demir, N; Dincer, M; Ozdemir, N; Erdem, D; Ak, N; Inal, A; Salim, DK; Deniz, GI; Sakalar, T; Gulmez, A; Kacan, T; Ozdemir, O; Alan, O; Unal, C; Karakas, Y; Turhal, S; Yumuk, PF
    Neoadjuvant chemotherapy (NACT) in gastroesophageal junction (GEJ) and gastric cancer (GC) was shown to improve survival in recent studies. We aimed to share our real-life experience of patients who received NACT to compare ...